Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kazmi

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
JCO Oncology Practice|January 11, 2021
Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net HospitalBenjamin D Fangman, Suleyman Y Goksu, Nivan Chowattukunnel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
JCO Oncology Practice|January 11, 2021
Disparities in Characteristics, Access to Care, and Oncologic Outcomes in Young-Onset Colorectal Cancer at a Safety-Net HospitalBenjamin D Fangman, Suleyman Y Goksu, Nivan Chowattukunnel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
Nature Communications|March 12, 2024
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trialDavid Hsiehchen, Muhammad S Beg, Radhika Kainthla, et al.
Pageof 6